title: Overactive mTOR signaling leads to endometrial hyperplasia in aged women and mice.
abstract: During aging, uncontrolled epithelial cell proliferation in the uterus results in endometrial hyperplasia and/or cancer development. The mTOR signaling pathway is one of the major regulators of aging as suppression of this pathway prolongs lifespan in model organisms. Genetic alterations in this pathway via mutations and/or amplifications are often encountered in endometrial cancers. However, the exact contribution of mTOR signaling and uterine aging to endometrial pathologies is currently unclear. This study examined the role of mTOR signaling in uterine aging and its implications in the development of endometrial hyperplasia. The hyperplastic endometrium of both postmenopausal women and aged mice exhibited elevated mTOR activity as seen with increased expression of the pS6 protein. Analysis of uteri from Pten heterozygous and Pten overexpressing mice further confirmed that over-activation of mTOR signaling leads to endometrial hyperplasia. Pharmacological inhibition of mTOR signaling using rapamycin treatment suppressed endometrial hyperplasia in aged mice. Furthermore, treatment with mTOR inhibitors reduced colony size and proliferation of a PTEN negative endometrial cancer cell line in 3D culture. Collectively, this study suggests that hyperactivation of the mTOR pathway is involved in the development of endometrial hyperplasia in aged women and mice.
authors.affiliation: Gynaecology Oncology Group, School of Biomedical Sciences and Pharmacy, Callaghan, New South Wales, Australia.
authors.forename: Preety
authors.initials: P
authors.lastname: Bajwa
authors.affiliation: Hunter Cancer Biobank, Callaghan, New South Wales, Australia.
authors.forename: Sarah
authors.initials: S
authors.lastname: Nielsen
authors.affiliation: School of Medicine and Public Health, University of Newcastle, Callaghan, New South Wales, Australia.|Department of Medical Oncology, Gynaecology Oncology, Calvary Mater Newcastle, Waratah, New South Wales, Australia.
authors.forename: Janine M
authors.initials: JM
authors.lastname: Lombard
authors.affiliation: Hunter Cancer Biobank, Callaghan, New South Wales, Australia.|School of Medicine and Public Health, University of Newcastle, Callaghan, New South Wales, Australia.
authors.forename: Loui
authors.initials: L
authors.lastname: Rassam
authors.affiliation: School of Medicine and Public Health, University of Newcastle, Callaghan, New South Wales, Australia.|Gynaecology and Obstetrics, John Hunter Hospital, New Lambton, New South Wales, Australia.
authors.forename: Pravin
authors.initials: P
authors.lastname: Nahar
authors.affiliation: Vincent Department of Obstetrics and Gynecology and Department of Obstetrics & Gynecology, Vincent Center for Reproductive Biology, Massachusetts General Hospital and Gynecologic Oncology Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
authors.forename: Bo R
authors.initials: BR
authors.lastname: Rueda
authors.affiliation: Department of Pathology, Unit for Laboratory Animal Medicine, University of Michigan School of Medicine, Ann Arbor, MI, USA.
authors.forename: J Erby
authors.initials: JE
authors.lastname: Wilkinson
authors.affiliation: Department of Pathology and Geriatrics Center, University of Michigan, Ann Arbor, MI, USA.
authors.forename: Richard A
authors.initials: RA
authors.lastname: Miller
authors.affiliation: Gynaecology Oncology Group, School of Biomedical Sciences and Pharmacy, Callaghan, New South Wales, Australia.
authors.forename: Pradeep S
authors.initials: PS
authors.lastname: Tanwar
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D004714:Endometrial Hyperplasia / Q000201:enzymology* / Q000235:genetics / Q000473:pathology / Q000517:prevention & control; D016889:Endometrial Neoplasms / Q000188:drug therapy / Q000201:enzymology / Q000473:pathology; D004717:Endometrium / Q000187:drug effects / Q000201:enzymology* / Q000473:pathology; D004847:Epithelial Cells / Q000187:drug effects / Q000201:enzymology* / Q000473:pathology; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D051059:PTEN Phosphohydrolase / Q000235:genetics / Q000378:metabolism; D010641:Phenotype; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D015398:Signal Transduction / Q000187:drug effects; D020123:Sirolimus / Q000494:pharmacology; D018874:Spheroids, Cellular; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism*
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; C546842:MTOR protein, human; C546843:mTOR protein, mouse; D058570:TOR Serine-Threonine Kinases; D051059:PTEN Phosphohydrolase; C494929:PTEN protein, human; C487757:Pten protein, mouse; D020123:Sirolimus
keywords: Gerotarget; PI3K; Pten; aging; endometrial; mTOR; rapalogs